Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery

Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery

Background: Systemic treatment options for metastatic renal cell carcinoma (RCC) have significantly expanded in recent years. However, patients refractory to tyrosine kinase and immune checkpoint inhibitors still have limited treatment options and patient-individualized approaches are largely missin...

Full description

Bibliographic Details
Main Authors: Jielin Li, Laura Pohl, Julia Schüler, Nina Korzeniewski, Philipp Reimold, Adam Kaczorowski, Weibin Hou, Stefanie Zschäbitz, Cathleen Nientiedt, Dirk Jäger, Markus Hohenfellner, Anette Duensing, Stefan Duensing
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Biomedicines
Subjects:
renal cell carcinoma
drug screening
proteasome inhibitor
carfilzomib
Online Access:https://www.mdpi.com/2227-9059/9/6/627

Internet

https://www.mdpi.com/2227-9059/9/6/627

Similar Items